Intravitreal panitumumab and retinal pigment epithelium proliferation in laser-induced retinal degeneration in rabbits
This study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal pigment epithelium cells (RPE) in an experimental model of localized retinal degeneration. The experimental study included rabbits with age of 2...
Uložené v:
| Vydané v: | Frontiers in ophthalmology Ročník 5; s. 1641194 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Switzerland
Frontiers Media S.A
07.08.2025
|
| Predmet: | |
| ISSN: | 2674-0826, 2674-0826 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | This study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal pigment epithelium cells (RPE) in an experimental model of localized retinal degeneration.
The experimental study included rabbits with age of 2 to 3 months and body weight of 2.5-3 kg and which were randomly distributed into a study group and control group. The right eyes received two retinal argon laser coagulation spots (500 mW; diameter, 100 μm; duration, 0.5 s), applied with an interval of 2 min at the same location close to the vascular streak in the posterior fundus region. For five times at 2-day intervals, the rabbits of the study group received intravitreal injections of 1 mg panitumumab (0.10 mL), and the rabbits of the control group had intravitreal injections of 0.10 mL Ringer's solution. At baseline, at each time point of re-examination, and at study end, the animals were examined by fundus photography and optical coherence tomography of the laser spot.
The study included 19 rabbits (study group: 10 animals; control group: nine animals). After the third injection and at study end, the laser-induced area of depigmentation + hyperpigmentation combined did not vary significantly between the study group and the control group (1.43 ± 0.63 mm
versus 1.63 ± 0.77 mm
;
= 0.56; and 1.37 ± 0.63 mm
versus 1.61 ± 0.74 mm
;
= 0.46, respectively). At the same time points, the area with hyperpigmentation was significantly smaller in the study group than in the control group (0.16 ± 0.15 mm
versus 0.80 ± 0.59 mm
;
= 0.01; and 0.14 ± 0.14 mm
versus 0.70 ± 0.56 mm
;
= 0.02, respectively). At the same time points, the ratio of the hyperpigmented area to the combined depigmented + hyperpigmented area was significantly smaller in the study group than in the control group (0.11 ± 0.09 versus 0.43 ± 0.19 mm
;
< 0.001; and 0.10 ± 0.08 versus 0.35 ± 0.23mm
;
= 0.006, respectively).
These findings indicate that intravitreally administered panitumumab was associated with reduced subretinal hyperpigmentation in a laser-induced model of retinal injury. While this may reflect a modulation of the RPE response, including the potential suppression of RPE proliferation, further studies incorporating histological and molecular analyses are warranted to confirm its effect on subretinal fibrosis. |
|---|---|
| AbstractList | This study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal pigment epithelium cells (RPE) in an experimental model of localized retinal degeneration.PurposeThis study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal pigment epithelium cells (RPE) in an experimental model of localized retinal degeneration.The experimental study included rabbits with age of 2 to 3 months and body weight of 2.5-3 kg and which were randomly distributed into a study group and control group. The right eyes received two retinal argon laser coagulation spots (500 mW; diameter, 100 μm; duration, 0.5 s), applied with an interval of 2 min at the same location close to the vascular streak in the posterior fundus region. For five times at 2-day intervals, the rabbits of the study group received intravitreal injections of 1 mg panitumumab (0.10 mL), and the rabbits of the control group had intravitreal injections of 0.10 mL Ringer's solution. At baseline, at each time point of re-examination, and at study end, the animals were examined by fundus photography and optical coherence tomography of the laser spot.MethodsThe experimental study included rabbits with age of 2 to 3 months and body weight of 2.5-3 kg and which were randomly distributed into a study group and control group. The right eyes received two retinal argon laser coagulation spots (500 mW; diameter, 100 μm; duration, 0.5 s), applied with an interval of 2 min at the same location close to the vascular streak in the posterior fundus region. For five times at 2-day intervals, the rabbits of the study group received intravitreal injections of 1 mg panitumumab (0.10 mL), and the rabbits of the control group had intravitreal injections of 0.10 mL Ringer's solution. At baseline, at each time point of re-examination, and at study end, the animals were examined by fundus photography and optical coherence tomography of the laser spot.The study included 19 rabbits (study group: 10 animals; control group: nine animals). After the third injection and at study end, the laser-induced area of depigmentation + hyperpigmentation combined did not vary significantly between the study group and the control group (1.43 ± 0.63 mm2 versus 1.63 ± 0.77 mm2; P = 0.56; and 1.37 ± 0.63 mm2 versus 1.61 ± 0.74 mm2; P = 0.46, respectively). At the same time points, the area with hyperpigmentation was significantly smaller in the study group than in the control group (0.16 ± 0.15 mm2 versus 0.80 ± 0.59 mm2; P = 0.01; and 0.14 ± 0.14 mm2 versus 0.70 ± 0.56 mm2; P = 0.02, respectively). At the same time points, the ratio of the hyperpigmented area to the combined depigmented + hyperpigmented area was significantly smaller in the study group than in the control group (0.11 ± 0.09 versus 0.43 ± 0.19 mm2; P < 0.001; and 0.10 ± 0.08 versus 0.35 ± 0.23mm2; P = 0.006, respectively).ResultsThe study included 19 rabbits (study group: 10 animals; control group: nine animals). After the third injection and at study end, the laser-induced area of depigmentation + hyperpigmentation combined did not vary significantly between the study group and the control group (1.43 ± 0.63 mm2 versus 1.63 ± 0.77 mm2; P = 0.56; and 1.37 ± 0.63 mm2 versus 1.61 ± 0.74 mm2; P = 0.46, respectively). At the same time points, the area with hyperpigmentation was significantly smaller in the study group than in the control group (0.16 ± 0.15 mm2 versus 0.80 ± 0.59 mm2; P = 0.01; and 0.14 ± 0.14 mm2 versus 0.70 ± 0.56 mm2; P = 0.02, respectively). At the same time points, the ratio of the hyperpigmented area to the combined depigmented + hyperpigmented area was significantly smaller in the study group than in the control group (0.11 ± 0.09 versus 0.43 ± 0.19 mm2; P < 0.001; and 0.10 ± 0.08 versus 0.35 ± 0.23mm2; P = 0.006, respectively).These findings indicate that intravitreally administered panitumumab was associated with reduced subretinal hyperpigmentation in a laser-induced model of retinal injury. While this may reflect a modulation of the RPE response, including the potential suppression of RPE proliferation, further studies incorporating histological and molecular analyses are warranted to confirm its effect on subretinal fibrosis.ConclusionsThese findings indicate that intravitreally administered panitumumab was associated with reduced subretinal hyperpigmentation in a laser-induced model of retinal injury. While this may reflect a modulation of the RPE response, including the potential suppression of RPE proliferation, further studies incorporating histological and molecular analyses are warranted to confirm its effect on subretinal fibrosis. PurposeThis study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal pigment epithelium cells (RPE) in an experimental model of localized retinal degeneration.MethodsThe experimental study included rabbits with age of 2 to 3 months and body weight of 2.5–3 kg and which were randomly distributed into a study group and control group. The right eyes received two retinal argon laser coagulation spots (500 mW; diameter, 100 μm; duration, 0.5 s), applied with an interval of 2 min at the same location close to the vascular streak in the posterior fundus region. For five times at 2-day intervals, the rabbits of the study group received intravitreal injections of 1 mg panitumumab (0.10 mL), and the rabbits of the control group had intravitreal injections of 0.10 mL Ringer’s solution. At baseline, at each time point of re-examination, and at study end, the animals were examined by fundus photography and optical coherence tomography of the laser spot.ResultsThe study included 19 rabbits (study group: 10 animals; control group: nine animals). After the third injection and at study end, the laser-induced area of depigmentation + hyperpigmentation combined did not vary significantly between the study group and the control group (1.43 ± 0.63 mm2 versus 1.63 ± 0.77 mm2; P = 0.56; and 1.37 ± 0.63 mm2 versus 1.61 ± 0.74 mm2; P = 0.46, respectively). At the same time points, the area with hyperpigmentation was significantly smaller in the study group than in the control group (0.16 ± 0.15 mm2 versus 0.80 ± 0.59 mm2; P = 0.01; and 0.14 ± 0.14 mm2 versus 0.70 ± 0.56 mm2; P = 0.02, respectively). At the same time points, the ratio of the hyperpigmented area to the combined depigmented + hyperpigmented area was significantly smaller in the study group than in the control group (0.11 ± 0.09 versus 0.43 ± 0.19 mm2; P < 0.001; and 0.10 ± 0.08 versus 0.35 ± 0.23mm2; P = 0.006, respectively)ConclusionsThese findings indicate that intravitreally administered panitumumab was associated with reduced subretinal hyperpigmentation in a laser-induced model of retinal injury. While this may reflect a modulation of the RPE response, including the potential suppression of RPE proliferation, further studies incorporating histological and molecular analyses are warranted to confirm its effect on subretinal fibrosis. This study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal pigment epithelium cells (RPE) in an experimental model of localized retinal degeneration. The experimental study included rabbits with age of 2 to 3 months and body weight of 2.5-3 kg and which were randomly distributed into a study group and control group. The right eyes received two retinal argon laser coagulation spots (500 mW; diameter, 100 μm; duration, 0.5 s), applied with an interval of 2 min at the same location close to the vascular streak in the posterior fundus region. For five times at 2-day intervals, the rabbits of the study group received intravitreal injections of 1 mg panitumumab (0.10 mL), and the rabbits of the control group had intravitreal injections of 0.10 mL Ringer's solution. At baseline, at each time point of re-examination, and at study end, the animals were examined by fundus photography and optical coherence tomography of the laser spot. The study included 19 rabbits (study group: 10 animals; control group: nine animals). After the third injection and at study end, the laser-induced area of depigmentation + hyperpigmentation combined did not vary significantly between the study group and the control group (1.43 ± 0.63 mm versus 1.63 ± 0.77 mm ; = 0.56; and 1.37 ± 0.63 mm versus 1.61 ± 0.74 mm ; = 0.46, respectively). At the same time points, the area with hyperpigmentation was significantly smaller in the study group than in the control group (0.16 ± 0.15 mm versus 0.80 ± 0.59 mm ; = 0.01; and 0.14 ± 0.14 mm versus 0.70 ± 0.56 mm ; = 0.02, respectively). At the same time points, the ratio of the hyperpigmented area to the combined depigmented + hyperpigmented area was significantly smaller in the study group than in the control group (0.11 ± 0.09 versus 0.43 ± 0.19 mm ; < 0.001; and 0.10 ± 0.08 versus 0.35 ± 0.23mm ; = 0.006, respectively). These findings indicate that intravitreally administered panitumumab was associated with reduced subretinal hyperpigmentation in a laser-induced model of retinal injury. While this may reflect a modulation of the RPE response, including the potential suppression of RPE proliferation, further studies incorporating histological and molecular analyses are warranted to confirm its effect on subretinal fibrosis. |
| Author | Nizamutdinova, Aigul M. Bikbov, Mukharram M. Valishin, Iskander D. Kazakbaeva, Gyulli M. Panda-Jonas, Songhomitra Jonas, Jost B. |
| AuthorAffiliation | 8 Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong , Hong Kong , Hong Kong SAR, China 4 Privatpraxis Prof Jonas und Dr Panda-Jonas , Heidelberg , Germany 3 L V Prasad Eye Institute , Hyderabad, Telangana , India 6 Singapore Eye Research Institute, Singapore National Eye Center , Singapore , Singapore 1 Ufa Eye Research Institute, Bashkir State Medical University , Ufa , Russia 5 Rothschild Foundation Hospital, Institut Français de Myopie , Paris , France 7 Beijing Visual Science and Translational Eye Research Institute (BERI), Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University , Beijing , China 2 Department of Ophthalmology, Medical Faculty Heidelberg, Heidelberg University , Heidelberg , Germany 9 New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai , New York, NY , United States |
| AuthorAffiliation_xml | – name: 2 Department of Ophthalmology, Medical Faculty Heidelberg, Heidelberg University , Heidelberg , Germany – name: 7 Beijing Visual Science and Translational Eye Research Institute (BERI), Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University , Beijing , China – name: 8 Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong , Hong Kong , Hong Kong SAR, China – name: 4 Privatpraxis Prof Jonas und Dr Panda-Jonas , Heidelberg , Germany – name: 3 L V Prasad Eye Institute , Hyderabad, Telangana , India – name: 6 Singapore Eye Research Institute, Singapore National Eye Center , Singapore , Singapore – name: 1 Ufa Eye Research Institute, Bashkir State Medical University , Ufa , Russia – name: 5 Rothschild Foundation Hospital, Institut Français de Myopie , Paris , France – name: 9 New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai , New York, NY , United States |
| Author_xml | – sequence: 1 givenname: Mukharram M. surname: Bikbov fullname: Bikbov, Mukharram M. – sequence: 2 givenname: Gyulli M. surname: Kazakbaeva fullname: Kazakbaeva, Gyulli M. – sequence: 3 givenname: Songhomitra surname: Panda-Jonas fullname: Panda-Jonas, Songhomitra – sequence: 4 givenname: Iskander D. surname: Valishin fullname: Valishin, Iskander D. – sequence: 5 givenname: Aigul M. surname: Nizamutdinova fullname: Nizamutdinova, Aigul M. – sequence: 6 givenname: Jost B. surname: Jonas fullname: Jonas, Jost B. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40852622$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkk1v1DAQhi1URD_oH-CAcuSSxV-J7RNCFdCVKnGBs-XE411XiR1sZyX-fZPuUranGc2884w0816jixADIPSB4A1jUn12cdqXDcW02ZCWE6L4G3RFW8FrLGl7cZZfotucHzHGVIpGcfUOXXIsG9pSeoUO21CSOfiSwAzVZIIv8ziPpqtMsFWC4sNa97sRQqlg8mUPg5_Hakpx8A6SKT6GyodqMBlS7YOde_g_aWEH4UyVTNf5kt-jt84MGW5P8Qb9_v7t1919_fDzx_bu60Pdc0pLLRk3xFmKLQiz5oIIJzvc9LJzjWwUwS3pFFUS94L0wjkl275R1hLiOHXsBm2PXBvNo56SH036q6Px-rkQ006bVHw_gG6FNQAttUY4rtRyOdEASAOUMdtYsrC-HFnT3I1ge1gvN7yCvu4Ev9e7eNCEsuUXii2ETydCin9myEWPPvcwDCZAnLNmlLesoUKIRfrxfNnLln-fWwT0KOhTzDmBe5EQrFeH6GeH6NUh-uQQ9gS6irKR |
| Cites_doi | 10.1016/S0140-6736(18)31550-2 10.1016/j.ophtha.2013.10.023 10.1159/000101926 10.1007/s00417-011-1673-1 10.1136/bjo-2023-323383 10.1016/S2214-109X(17)30393-5 10.2741/S398 10.1016/S2214-109X(13)70113-X 10.1136/gut.38.4.582 10.1006/exer.1998.0517 10.1016/0896-6273(91)90233-P 10.1159/000077330 10.1007/s00417-021-05200-5 10.1016/S0022-3468(05)80305-7 10.1016/0014-4835(92)90122-9 10.1128/IAI.66.10.4917-4923.1998 10.1056/NEJMoa054481 10.1007/s10792-021-01761-w 10.1016/S0140-6736(12)60272-4 10.1096/fj.202001095RR 10.1097/00006982-199212020-00009 10.1038/s41598-021-01500-2 10.1016/S0140-6736(12)60282-7 10.1038/s41598-022-15642-4 10.1111/j.1755-3768.2012.02414.x 10.1152/ajpgi.1993.265.3.G459 10.1038/nbt1337 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Bikbov, Kazakbaeva, Panda-Jonas, Valishin, Nizamutdinova and Jonas. Copyright © 2025 Bikbov, Kazakbaeva, Panda-Jonas, Valishin, Nizamutdinova and Jonas. 2025 Bikbov, Kazakbaeva, Panda-Jonas, Valishin, Nizamutdinova and Jonas |
| Copyright_xml | – notice: Copyright © 2025 Bikbov, Kazakbaeva, Panda-Jonas, Valishin, Nizamutdinova and Jonas. – notice: Copyright © 2025 Bikbov, Kazakbaeva, Panda-Jonas, Valishin, Nizamutdinova and Jonas. 2025 Bikbov, Kazakbaeva, Panda-Jonas, Valishin, Nizamutdinova and Jonas |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fopht.2025.1641194 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2674-0826 |
| ExternalDocumentID | oai_doaj_org_article_67daee62da7f49908275ee8ae233d5d1 PMC12367493 40852622 10_3389_fopht_2025_1641194 |
| Genre | Journal Article |
| GroupedDBID | 9T4 AAFWJ AAYXX AFPKN ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ PGMZT RPM NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c422t-834a1fd20de7a34a1717f8b05c8bf58591061b92980c71c7ff986c59dd11f42f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001554575700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2674-0826 |
| IngestDate | Fri Oct 03 12:52:09 EDT 2025 Sat Aug 23 05:22:16 EDT 2025 Thu Sep 04 12:31:04 EDT 2025 Tue Sep 16 01:45:39 EDT 2025 Sat Nov 29 07:40:48 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | retinal pigment epithelium panitumumab epidermal growth factor receptor inhibitor intravitreal medication macular degeneration macular scar |
| Language | English |
| License | Copyright © 2025 Bikbov, Kazakbaeva, Panda-Jonas, Valishin, Nizamutdinova and Jonas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c422t-834a1fd20de7a34a1717f8b05c8bf58591061b92980c71c7ff986c59dd11f42f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Peter Koulen, University of Missouri–Kansas City, United States Reviewed by: Ditsha Datta, Sankar Foundation Eye Hospital, India Jin-Ho Joo, Chung-Ang University, Republic of Korea |
| OpenAccessLink | https://doaj.org/article/67daee62da7f49908275ee8ae233d5d1 |
| PMID | 40852622 |
| PQID | 3246352777 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_67daee62da7f49908275ee8ae233d5d1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12367493 proquest_miscellaneous_3246352777 pubmed_primary_40852622 crossref_primary_10_3389_fopht_2025_1641194 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-08-07 |
| PublicationDateYYYYMMDD | 2025-08-07 |
| PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in ophthalmology |
| PublicationTitleAlternate | Front Ophthalmol (Lausanne) |
| PublicationYear | 2025 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Grossniklaus (B9) 1992; 12 Buchmiller (B27) 1993; 28 Anchan (B13) 1991; 6 Kissmeyer-Nielsen (B29) 1996; 38 Bourne (B1) 2013; 1 Rosenfeld (B6) 2006; 355 Jonas (B10) 2021; 11 Buret (B26) 1998; 66 Wolf (B8) 2014; 121 Flaxman (B2) 2017; 5 Kociok (B15) 1998; 67 Martin (B7) 2014; 121 Jonas (B20) 2012; 90 Spraul (B16) 2004; 36 Bikbov (B22) 2021; 41 Yan (B11) 2007; 221 Zhang (B18) 2013; 5 Foltzer-Jourdaine (B28) 1993; 265 Jonas (B21) 2021; 259 Lim (B3) 2012; 379 Mitchell (B4) 2018; 392 Jakobovits (B25) 2007; 25 Liu (B14) 1992; 55 Bikbov (B24) 2024; 108 Steindl-Kuscher (B17) 2011; 249 Dong (B19) 2020; 34 Leschey (B12) 1990; 31 Bikbov (B23) 2022; 12 Morgan (B5) 2012; 379 |
| References_xml | – volume: 392 year: 2018 ident: B4 article-title: Age-related macular degeneration publication-title: Lancet doi: 10.1016/S0140-6736(18)31550-2 – volume: 121 year: 2014 ident: B7 article-title: RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.10.023 – volume: 221 year: 2007 ident: B11 article-title: Epidermal growth factor receptor in cultured human retinal pigment epithelial cells publication-title: Ophthalmologica doi: 10.1159/000101926 – volume: 249 year: 2011 ident: B17 article-title: Epidermal growth factor: the driving force in initiation of RPE cell proliferation publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-011-1673-1 – volume: 108 year: 2024 ident: B24 article-title: Intravitreal panitumumab and myopic macular degeneration publication-title: Br J Ophthalmol doi: 10.1136/bjo-2023-323383 – volume: 5 year: 2017 ident: B2 article-title: Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(17)30393-5 – volume: 5 year: 2013 ident: B18 article-title: Migration of retinal pigment epithelial cells is EGFR/PI3K/AKT dependent publication-title: Front Biosci (Schol Ed) doi: 10.2741/S398 – volume: 1 year: 2013 ident: B1 article-title: Causes of vision loss worldwide, 1990-2010: a systematic analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(13)70113-X – volume: 38 year: 1996 ident: B29 article-title: Effects of longterm epidermal growth factor treatment on the normal rat colon publication-title: Gut doi: 10.1136/gut.38.4.582 – volume: 67 year: 1998 ident: B15 article-title: The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells publication-title: Exp Eye Res doi: 10.1006/exer.1998.0517 – volume: 121 year: 2014 ident: B8 article-title: RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia publication-title: Ophthalmology doi: 10.1016/j.ophtha.2013.10.023 – volume: 6 year: 1991 ident: B13 article-title: EGF and TGF-alpha stimulate retinal neuroepithelial cell proliferation in vitro publication-title: Neuron doi: 10.1016/0896-6273(91)90233-P – volume: 36 year: 2004 ident: B16 article-title: Effect of growth factors on bovine retinal pigment epithelial cell migration and proliferation publication-title: Ophthalmic Res doi: 10.1159/000077330 – volume: 259 year: 2021 ident: B21 article-title: Intraocular epidermal growth factor concentration, axial length, and high axial myopia publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-021-05200-5 – volume: 28 year: 1993 ident: B27 article-title: Effect of transamniotic administration of epidermal growth factor on fetal rabbit small intestinal nutrient transport and disaccharidase development publication-title: J Pediatr Surg doi: 10.1016/S0022-3468(05)80305-7 – volume: 55 year: 1992 ident: B14 article-title: Epidermal growth factor potentiates the transmitter-induced stimulation of C-AMP and inositol phosphates in human pigment epithelial cells in culture publication-title: Exp Eye Res doi: 10.1016/0014-4835(92)90122-9 – volume: 66 year: 1998 ident: B26 article-title: Effects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits publication-title: Infect Immun doi: 10.1128/IAI.66.10.4917-4923.1998 – volume: 355 year: 2006 ident: B6 article-title: Ranibizumab for neovascular age-related macular degeneration publication-title: N Engl J Med doi: 10.1056/NEJMoa054481 – volume: 41 year: 2021 ident: B22 article-title: Compatibility of intravitreally applied epidermal growth factor and amphiregulin publication-title: Int Ophthalmol doi: 10.1007/s10792-021-01761-w – volume: 379 year: 2012 ident: B5 article-title: Myopia publication-title: Lancet doi: 10.1016/S0140-6736(12)60272-4 – volume: 34 year: 2020 ident: B19 article-title: Blockade of epidermal growth factor and its receptor and axial elongation in experimental myopia publication-title: FASEB. J doi: 10.1096/fj.202001095RR – volume: 12 year: 1992 ident: B9 article-title: Pathologic findings in pathologic myopia publication-title: Retina doi: 10.1097/00006982-199212020-00009 – volume: 11 start-page: 21908 year: 2021 ident: B10 article-title: Histology of neovascular myopic macular degeneration publication-title: Sci Rep doi: 10.1038/s41598-021-01500-2 – volume: 379 year: 2012 ident: B3 article-title: Age-related macular degeneration publication-title: Lancet doi: 10.1016/S0140-6736(12)60282-7 – volume: 31 year: 1990 ident: B12 article-title: Growth factor responsiveness of human retinal pigment epithelial cells publication-title: Invest. Ophthalmol Vis Sci – volume: 12 start-page: 11454 year: 2022 ident: B23 article-title: Safety and tolerability of intravitreal cetuximab in young and adult rabbits publication-title: Sci Rep doi: 10.1038/s41598-022-15642-4 – volume: 90 year: 2012 ident: B20 article-title: Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration publication-title: Acta Ophthalmol doi: 10.1111/j.1755-3768.2012.02414.x – volume: 265 year: 1993 ident: B28 article-title: Epidermal growth factor and the maturation of intestinal sucrase in suckling rats publication-title: Am J Physiol doi: 10.1152/ajpgi.1993.265.3.G459 – volume: 25 year: 2007 ident: B25 article-title: From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice publication-title: Nat Biotechnol doi: 10.1038/nbt1337 |
| SSID | ssj0002875949 |
| Score | 2.2998443 |
| Snippet | This study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of retinal... PurposeThis study aims to examine the effect of intravitreally applied epidermal growth factor (EGF) receptor blocker panitumumab on the proliferation of... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1641194 |
| SubjectTerms | epidermal growth factor receptor inhibitor intravitreal medication macular degeneration macular scar Ophthalmology panitumumab retinal pigment epithelium |
| Title | Intravitreal panitumumab and retinal pigment epithelium proliferation in laser-induced retinal degeneration in rabbits |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40852622 https://www.proquest.com/docview/3246352777 https://pubmed.ncbi.nlm.nih.gov/PMC12367493 https://doaj.org/article/67daee62da7f49908275ee8ae233d5d1 |
| Volume | 5 |
| WOSCitedRecordID | wos001554575700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2674-0826 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002875949 issn: 2674-0826 databaseCode: DOA dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVKVSEuFZSPbguVkXpDoYljx_YREBUcqHqg0t4sxx9tUDcb7W7293fGyZZdhMSFW5TYieU30byxx28IOY88L7XTYLy5DxmXAv85lWdchFgqH2pR-FRsQl5dqelUX2-V-sKcsEEeeJi4i0p6G0LFvJUR2Dl4LClCUDawsvTCp8AHWM9WMPUrLRlJobkeTslAFKYv4ry7w9xJJj5ChFAUmu94oiTY_zeW-Wey5Jb3uXxODkfaSD8Nw31B9kJ7RJ7-GDfGX5L1d-y2bjBv_J52qGnRz_qZraltPcWTiti9a25xMZCGDk9i3Df9jHZYtSeGwQ5o01Jg02GRQaQOmP_u6cNt0qfetFrYum5Wy1fk5vLrzy_fsrGkQuY4Y6tMldwW0TMARlq8hmguqjoXTtVRoJYd-PcaKJPKnSycjFGrygntfVFEzmL5muy38zYcE5pb4E4-h4gk97xwlYI31Y4LyYVXZZQT8mEzvaYblDMMRBwIhklgGATDjGBMyGdE4LElql6nG2ALZrQF8y9bmJD3G_wM_CW49WHbMO-XBmgjMCsmJQzrzYDn46dQ441VjE2I2kF6Zyy7T9rmLilxJ_07rsuT_zH6U_IMZyRlF8q3ZH-16MM7cuDWq2a5OCNP5FSdJSt_AFaZBHI |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intravitreal+panitumumab+and+retinal+pigment+epithelium+proliferation+in+laser-induced+retinal+degeneration+in+rabbits&rft.jtitle=Frontiers+in+ophthalmology&rft.au=Bikbov%2C+Mukharram+M.&rft.au=Kazakbaeva%2C+Gyulli+M.&rft.au=Panda-Jonas%2C+Songhomitra&rft.au=Valishin%2C+Iskander+D.&rft.date=2025-08-07&rft.issn=2674-0826&rft.eissn=2674-0826&rft.volume=5&rft_id=info:doi/10.3389%2Ffopht.2025.1641194&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fopht_2025_1641194 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2674-0826&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2674-0826&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2674-0826&client=summon |